At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 451 enrolled
Drug / intervention
Prednisolone +1 moredrug
Likely dose
Prednisolone 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid Arthritis
In Brief
A Phase 4 clinical trial evaluating Prednisolone and Placebo for RheumatoId Arthritis. Completed, enrolled 451 participants across 28 sites in 7 countries.
Detailed Summary
Comparing the cost-effectiveness and safety of additional low-dose glucocorticoid in treatment strategies for elderly patients with rheumatoid arthritis: The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study (GLORIA)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoId Arthritis
CountriesGermany, Hungary, Italy, Netherlands, Portugal, Romania, Slovakia
CollaboratorsEuropean Commission
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartJun 2016
Primary CompletionDec 2020
TodayJul 2026
First PostedOct 23, 2015
Enrollment StartJun 30, 2016
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 10.7 years ago
Interventions
Prednisolonedrug
1 capsule containing a tablet of 5 mg prednisolone/ day
Placebodrug
1 capsule containing a placebo tablet / day